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COST EFFECTIVE HUMAN PROTEIN C PURIFICATION 
FROM COHN FRACTION IV-l USING MINI-ANTIBODY 
Doh Gyeuhn Ahn 
August 5, 2005 
Protein C (PC) is an important anticoagulant, antithrombotic, and anti-
inflammatory in blood plasma. PC deficiency can lead to severe venous thrombotic 
events, including lung embolism, stroke, and heart attack. In the body, PC is activated 
only when it is needed, and, therefore, PC does not cause bleeding problems that 
currently available anticoagulants may do. 
Purification of PC from plasma IS currently done by immunoaffinity 
chromatography using monoclonal antibodies (Mabs), which is very expensive. Single 
chain variable regions (mini-Mab) with a PC binding capability, which can b(: produced 
in recombinant E. coli, were developed for PC purification. Compared to Mabs, mini-
Mabs are easier to control the contamination during the production, with lower 
production cost, and easier to scale-up the process. In this Ph.D. research, the effect of 
media conditions on the PC mini-Mab production, the mini-Mab purification yield from 
the production media, and the PC purification performance of the mini-Mab from Cohn 
Fraction IV -1 (an inexpensive PC source) were studied. 
The optimum conditions for mini-Mab production medium were detemlined to be 
0.1 % glucose, 0.1 mM IPTG, initial pH 5.5~6.0, 23~30 °c of media temperature during 
v 
the production, and 18 hours of mini-Mab production time. The final mini-Mab 
production level became 450 mg/L. 
Mini-Mab in the production medium broth was purified using protein A affinity 
chromatography. A purification yield of 34 % was obtained using the elution pH of 3.0. 
For PC purification using the PC mini-Mab, among four commercially available 
affinity chromatography matrices, NHS Sepharose showed the best performance. The PC 
mini-Mab immobilized NHS Sepharose, when Cohn Fraction IV -1 is used as the source 
material, showed a PC purification yield of 16 %. High human serum albumin (HSA) 
content in the source material was found to reduce PC purification yield significantly. 
Therefore, anion exchange chromatography (DEAE) was used for the pretreatment of the 
Cohn Fraction IV-I before the affinity chromatography. DEAE chromatography 
removed over 99 % of the human serum albumin from Cohn Fraction IV-I. The PC 
purification yield from the eluate of DEAE chromatography of Cohn Fraction IV -1 was 
approximately 25 %, increasing by approximately 10 %. PC production cost using the 
mini-Mab immobilized NHS-Sepharose matrix was estimated to be approximately 100 
times cheaper than that using regular Mab. 
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Protein C (PC) is a vitamin K dependent glycoprotein in blood plasma. PC 
prevents the blood clotting in the blood vessels (anti-coagulant), dissolves the formed 
blood clots indirectly (anti-thrombosis), and prevents inflammation (anti-inflammation) 
(Esmon, et aI., 1999). 
When a person has a PC deficiency, blood clots may be formed inside blood 
vessels and these may cause thromboembolic symptoms, such as, lung embolism, heart 
attack, or stroke. 
Anticoagulant drugs, such as warfarin (coumarin) and heparin, are used for the 
patient who has thromboembolic events. Warfarin is a vitamin K analog and blocks the 
production pathway of the vitamin K dependent blood coagulant factors (Hirsh, et aI., 
1998a). However, it frequently causes bleeding problem. Heparin is working as an 
anticoagulant catalyzing the inactivation of thrombin and activated human factor IX 
(Hirsh, et aI., 1998b). It may also cause side effects of heparin induced 
thrombocytopenia (HIT) and bleeding problem. 
In plasma, PC exists as an inactive form (zymogen) at a concentration of 4 Ilg/mI. 
It is activated only when it is needed and, therefore, PC does not have the side effects that 
warfarin and heparin have. 
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The frequency of homozygous and heterozygous PC deficiency together in all the 
thrombotic events is 10 %. The other 10 % of thrombosis in the thrombotic events occurs 
in people in surgery, pregnancy, oral contraceptive, etc. showing acquired PC deficiency 
(Tabernero, et ai., 1991; MaIm, et ai., 1992; Allaart, et ai., 1994). 
Currently, from plasma, PC is purified using mouse monoclonal antibody as the 
ligand of affinity chromatography. Ceprotin TM, human plasma PC purified by the mouse 
monoclonal antibody (Mab) against PC (Schoppmann, et ai., 2001), has been licensed in 
European countries for patients with a severe congenital PC deficiency (Baxter 
International, Inc., 2001). The cost ofCeprotin™ is $78.5 per 100 /-Lg. 
To reduce the PC purification cost, single chain variable regions (mini-Mab) of 
the Mab against PC was developed by way of phage display method using human V -gene 
library (Wu, et ai., 1998b). Thirteen recombinant E. coli HB2151 colonies, which 
produce the mini-Mab against PC, were provided by Dr. Michael Sierks at the Arizona 
State University. A preliminary study of the mini-Mab purification, the PC purification 
using the purified mini-Mab, and an economic analysis of PC production using mini-Mab 
compared with that using Mab were performed by Korah, et al. (2003). 
In this dissertation, the results of three different studies are presented: (1) 
optimization of the mini-Mab production condition, (2) optimization of the mini-Mab 
purification process, and (3) the PC purification from Cohn Fraction IV -1 using the 





Protein C (PC) is a vitamin K dependent glycoprotein and it is produced in the 
liver as the form of zymogen (Stenflo, 1976; Esmon, 1990; Dreyfus, et al., 1991). In 
human blood plasma, the typical PC concentration level is 4 ~g/ml and the half-life of PC 
in blood plasma is 6-10 hours (Riess, et al., 1985; Miletich, et al., 1987; Okajima et al., 
1990; Dahlback, 1995). PC is converted to an activated PC (aPC) by thrombin-
thrombomodulin complex at the endothelial cells (Comp, et al., 1980; Marlar, et al., 
1981; Esmon, 1990). aPC stimulates anti-coagulation by deactivating activated 
coagulants, factors V and VIII (Kisiel, et al., 1977). aPC also inactivate plasminogen 
activator inhibitor (Marlar, et al., 1982) allowsing tissue plasminogen activator (tP A; 
antithrombotic agent) free. The free tPA converts plasminogen to plasmin and the 
plasmin degrades the formed blood clot (de Fouw, et al., 1988). aPC prevents 
inflammation by modulating inflammatory cytokine production and by blocking selectin-
mediated neutrophil binding (Esmon, 1990). The half-life of aPC in plasma is 15 to 30 
minutes (Esmon, 1990). 
There are three forms of PC deficiencies, homozygous, heterozygous, and 
acquired PC deficiencies. Homozygous PC deficient patients are born with two abnormal 
copies of the PC gene (Miletich, et al., 1993). Homozygous PC-deficient patients, 
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usually newborn infants, have very little of the functional PC in blood and, therefore, 
have severe thrombosis throughout the body including microvascular thrombosis in brain 
and wide spread intravascular coagulation. Without immediate clinical treatment, these 
conditions ultimately cause death. The frequency of homozygous PC deficiency is about 
1 in 250,000 to 500,000 births (Marlar, et aI., 1990). 
Heterozygous PC deficiency patients are born with a lower concentration of PC 
than that of normal people (Type 1) or with an abnormal copy of the PC gene (Type 2). 
Heterozygous PC-deficient patients are at risks of venous thrombotic events, including 
deep vein thrombosis, pulmonary embolism, stroke, and heart attack. Although they are 
not as urgent cases as those with the homozygous PC deficiency, the heterozygous PC 
deficiency exhibits symptoms in most individuals before 30 years of age (Sills, et aI., 
1984; All aart , et aI., 1995). The frequency of heterozygous PC deficiency is 0.1 to 0.5 
percent of the general population (Miletich, et aI., 1993). 
Each year, approximately 1 in 1,000 people, who do not have any genetic PC 
deficiency, at the age of 20 and 50, are affected by venous thrombosis (Goldhaber, et aI., 
1994). 3-10 % of these groups have a lower PC concentration level than the normal 
(Makris, et aI., 1997; Heijboer, et aI., 1990). These acquired PC deficiencies are 
associated with surgery, pregnancy, the use of oral contraceptives, Coumarin therapy, 
liver diseases, or body immobilization (Makris, et aI., 1997; MaIm, et aI., 1992; 
Tabernero, et aI., 1991; Allaart, et aI., 1994). 
Successful treatments for homozygous PC deficient patients using fresh-frozen 
PC-containing plasma have been reported (Marlar, et aI., 1990; Dreyfus, et aI., 1991). 
Frequent infusions of the fresh-frozen plasma, however, result in hyperproteinemia (Sills, 
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et aI., 1984). Ceprotin TM, human plasma PC concentrate without other clotting proteins 
has been licensed in European countries recently (Baxter International, Inc., 2001). 
Ceprotin ™ is for purpura fulminans and coumarin-induced skin necrosis in patients with 
a severe congenital PC deficiency. Ceprotin™ costs approximately $80 per 100 Ilg. 
Activated PC can be used also for the treatment of sepsis, which is the systemic 
response to severe bacteria infection in the blood and is associated with multiple organ 
dysfunctions (Bone, et aI., 1997). Sepsis has been reported as the leading causes of death 
in surgical intensive care units. Approximately 750,000 cases of sepsis occur in the 
United States each year (Bernard, et aI., 2001). The mortality rate of severe sepsis is 
approximately 20 % within 6 months (Rangel-Frausto, et aI., 1995). Recently, a 
recombinant human activated PC, XigrisTM, has been approved by the US Food and Drug 
Administration (FDA) to treat sepsis (Eli Lilly, 2001). The average wholesale prices of 
the 5 mg and 20 mg Xigris ™ are $210 and $840, respectively. The price for the 
recommended 96-hour dose (~0.2 g) is $7,700. 
Therefore, it is very important to provide cheap PC to PC-deficient patients, 
sepsis patients, patients having various thrombo-embolic episodes. 
B. PC SOURCES 
Currently available PC sources are human blood plasma (Schwarz, et aI., 1990), 
mammalian cell culture medium (Grinnell, et aI., 1990), and transgenic pig milk 
(Velander, et aI., 1992; Dalton, et aI., 1997). Human blood plasma is a natural source and 
has less immunogenic reactions in the human body. The production level of recombinant 
human PC (rhPC) from mammalian cell culture medium was reported to be 20 to 30 
5 
Ilg/ml/l06 cells/day from adenovirus transformed human kidney 293 cell lines (Grinnell, 
et aI., 1990). The rhPC production level in transgenic pig milk was reported at 380 Ilg/ml 
per hour from the mammary gland of a pig (Velander, et aI., 1992). However, the total 
recovery is only 24 % and PC production from transgenic pig milk requires many steps 
and large quantities of precipitation agents like polyethylene glycol (Wu, 2000; Wu, et 
aI.,2002). 
Commercially available cheap human plasma derived Cohn fraction IV -1 can be 
used as a volume reduced and enriched starting materials for producing pure PC 
(Vel ander, et aI., 1990). 
Cohn, et aI. have developed a method to fractionate many blood plasma proteins 
on a large scale, which were required in wartime (Creager, 1999). It was based on 
changing the solubility of the proteins using different pH values, temperatures, and 
ethanol concentrations. The plasma proteins were separated into five major fractions 
(Cohn, et aI., 1946): as much as possible of fibrinogen in Fraction I, y-globulins in 
Fraction II, lipid-bearing ~-globulins in Fraction III, a-globulins in Fraction IV, and 
albumins in Fraction V. To separate the proteins effectively, several methods were tried 
changing the ethanol concentration and pH (Figure 1). Cohn Fraction IV -1 is a 
byproduct of human serum albumin fractionation of blood plasma and usually discarded 
(Cohn, 1948). 
The Cohn Fraction IV -1 is known to include over 90 % of PC in Plasma, and 
coagulating factors, such as factors II, VII, IX, and X (Velander, et aI., 1990; Wu, et aI., 
1998a). 
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I Blood I 
I .[ Remove the red cells 
~ 
I Plasma I 
Fraction I PPT 
""'- L 8% EtOH, pH 7.2, _3°C 
(Fibrinogen) ! 
I Supernatant I 
Fraction II + III PPT L 25% EtOH, pH 6.8, _5°C 
(Prothrombin, p.-and y-globulin, ... - ~~ 
J plasminogen, isoagglutinin) 
I Supernatant I 
L r 18% EtOH, pH 5.2, _5°C J Fraction IV -1 PPT L I~ L 
~ 
I Supernatant I 
I 
L 40 % EtOH, pH 5.8, _5°C Fraction IV -4 PPT I~ 
(a- and p-globulin) .. 
I Supernatant I 
L L r 40% EtOH, pH 4.8, _5°C Fraction V PPT (HSA) L I .. 
I Supernatant I 
Figure 1. Schematic diagram of Cohn Fractionation. 
C. METHODS USED FOR THE PURIFICA nON OF PC FROM PLASMA 
1. Immuno-Affinity Chromatography 
Although human blood plasma and its derivatives are good sources of PC, they 
contain several proteins homologous to PC. Many of these homologues are coagulants, 
such as, Factors II, VII, IX and X (Foster, et aI., 1985; Furie, et aI., 1988; Leytus, et aI., 
1986; Y oshitake, et aI., 1985). Traditional chromatography methods other than immuno-
affinity method, therefore, may not be employed for PC purification. PC has been 
purified using immuno-affinity chromatography (Nakamura, et aI., 1987; Schoppmann, et 
aI., 2001; Schwarz, et aI., 1990). 
Nakamura, et aI. (1987) produced monoclonal antibodies and obtained 59.3 % of 
PC recovery by immunoaffinity chromatography. They reported also that 70 % of PC 
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was adsorbed on their monoclonal antibody using commercially available prothrombin 
complex concentrate, an eluate of anion exchange chromatography of human blood 
plasma in single step purification (Nakamura, et aI., 1987). 
Velander, et aI. (1990) have reported PC purification from an eluate of DEAE 
anion exchange chromatography of reconstituted Cohn Fraction IV-I. 2 mg of IgG was 
immobilized on 1 ml matrix. Using approximately 40 ml of the reconstituted Cohn 
Fraction IV -1 and 4 ml of the matrix, 25 % overall recovery of PC was obtained using 
direct immunopurification (Velander, et aI., 1990). 
Kang, et ai. (1992) developed a method for estimating the immunoaffinity PC 
purification performance using an affinity chromatography to estimate both the time and 
the cost of a large-scale PC purification process. The points to consider the mass 
production of PC are Mab adsorption efficiency on gel matrices, adsorption efficiency of 
PC to the immobilized Mab, and the specific activity of the eluted PC. In addition, it was 
reported that for the scale up of PC purification processes, pressure tolerance of the gel 
matrices and production rate should be considered. 
2.IMAC 
The cost of Mab production using animal cell culture is very high. Hence, PC 
purified using Mab is very expensive. Therefore, a much cheaper method than 
immunoaffinity chromatography, immobilized metal affinity chromatography (IMAC), 
was investigated to purify PC from Cohn Fraction IV -1 (Wu, et aI., 1998a; 1999). 
PC purification from prothrombin, a major coagulant factor in plasma, was 
studied using the mixture ofPe and prothrombin. IDA- copper ion was used and 95.5 % 
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of active PC was effectively recovered (Wu, et aI., 1999). Therefore, it was reported that 
copper IMAC may be cost effective method to purify PC from prothrombin instead of 
using immunoaffinity chromatography. 
For the PC purification from Cohn Fraction IV-l using iminodiacetic acid (IDA) 
and copper ion, 84 % of PC recovery was obtained (Wu, et aI, 1998a). However, the 
eluate included many contaminants based on gel electrophoresis, indicating that PC in 
Cohn Fraction IV -1 may not be separated by one step IMAC process (Wu, 2000) 
D. PC HOMOLOGUES 
Vitamin K dependent homologous proteins are factors II, VII, IX, and X as well 
as PC, protein S, and protein Z and all are produced in liver (Broze, et aI., 1984). Factors 
II, VII, IX, and X playa key role in blood clotting (Kisiel, et aI., 1977; Marlar, et aI., 
1982; Esmon, 1990). Protein S is acting as a cofactor of the activated PC to enhance the 
inactivation of the activated factor V and VIII (Griffin, et aI., 1999). Protein Z is 
considered to suppress thrombus formation inhibiting the activated factor X (McQuillan, 
et aI., 2003). 
The properties of vitamin K-dependent proteins were compared in Table 1. The 
molecular weights and the isoelectric points of the proteins are closely distributed at the 
range of between 50,000 and 72,000 kDa and between 4.0 and 5.5, respectively. 
Therefore, the separation of PC from these homologous proteins is a challenge. 
After separation of PC, several methods including gel electrophoresis, enzyme 
linked immunosorbent assay (ELISA), and the activity test may be required to 
characterize the purified PC. 
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Table 1. Properties of vitamin K-dependent proteins. 
Conc. Half Level Extinc. 
Proteins Molecular Function 
in life in Required Isoelectric Coeffi. Reference Weight plasma plasma for point (1% ) 
(J,lg/ml) (hours) Hemostasis Elcm,280nm 
Protein C 62,000 Anticoagulant 3.9-5.9 6-10 >60% 4.4 - 4.8 14.5 [24], [28], [33], 
[56], [66] 
Protein S 69,000 PC cofactor 20-35 15 >50% 5.0 - 5.5 9.5 
[24], [28], [33], 
(rabbit) [56] 
Protein Z 62,000 - 2.9 60 - - 12.0 [19], [24], [60] 
Factor II 72,000 Coagulant 80-90 48-120 20-40 % 4.7-4.9 13.8 
[24], [33], [34], 
[54], [56] 
Factor VII 50,000 Coagulant 0.47 4-7 10-20 % 4.8- 5.1 13.9 
[8], [17], [24], 
(bovine) [33], [56], [100] 
Factor IX 57,000 Coagulant 4-5 20-24 25-30 % 4.0-4.6 13.2 
[24], [33], [34], 
[56], [91] 
Factor X 59,000 Coagulant 6.4 24-40 10-20 % 4.8 - 5.0 11.6 
[24], [33], [34], 
[55], [56] 
E. MINI-ANTIBODY SPECIFIC AGAINST PC 
Immunoglobulin (IgG) is produced from B cell in the spleen and consists of four 
polypeptide chains (Figure 2). In an IgG molecule, two heavy chains and two light 
chains are held together by disulfide bonds. The antigen-binding site is at the amino end 
of each variable fragment (Lu, et aI., 1996). The antigen recognition region consists of 
one variable region in one heavy chain (V H) and one variable region in one light chain 
The heavy chain and light chain V -genes are shuffled at random and cloned for 
displaying as single chain variable fragments (scFvs) on the surface of filamentous phage 
to make the phage antibody library containing V -genes, and the phage-antibody 
fragments of the library are selected by binding to antigen. In addition, scFv with high 






Antigen binding sites ~ 
Fab 
(150 kDa) 
Figure 2. Structure ofMab. 
(Griffiths et aI., 1993; Marks, et aI., 1991). The mini-Mab against PC in this study was 
developed using the same V -genes (Wu, et aI., 1998). 
The phage library including V -genes specific to PC is isolated by a two-step 
selection procedure from the library (Wu, et aI., 1998b). First, undesired coagulant 
factors, Factor IX or Factor X, which are homologous proteins to PC, are coated on a 
solid support - a micro titer plate used for enzyme linked immunosorbent assay (ELISA). 
Advantages of producing mini-Mabs using the recombinant E. coli compared with 
Mabs include less contamination problems during production, less shear sensitivity of the 
host cell, less expense, and easier scale-up. 
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F. PREVIOUS STUDY ON PC PURIFICATION USING MINI-MAB 
Mini-Mab purification and PC purification using PC mini-Mab were initiated by 
Wu, et al. (1998b). Korah, et al. (2003) carried out preliminary, quantitative studies on 
mini-Mab purification and PC purification using the purified mini-Mab. The following 
studies were performed by Korah. 
Mini-Mab Production and Purification. The concentration of IPTG as an inducer 
in the mini-Mab production media was optimized from 1 mM to 0.1 mM. Mini-Mab was 
purified from the protein A immobilized CNBr-Sepharose chromatography. The 18 % of 
mini-Mab purification efficiency was obtained using an elution pH 3.0 of the glycine 
buffer. The metal ions of IMAC have affinity to histidine, cysteine, and tryptophan. 
Mini-Mab may contain these metal ion binding residues on the amino acid side chains of 
its surface. Therefore, mini-Mab purification was tested using IMAC column. The 
commercially available HiTrap Chelating IMAC column with a pre-immobilized chelator 
was used. Metal ions such as Ni2+, Cu2+, C02+, and Fe2+ were applied to the column. 
Cu2+ and C02+ were leached out during the mini-Mab adsorption at pH 7.4. Fe-IMAC 
showed only 0.3 % ofmini-Mab purification yield at pH 7.4. When Ni-NTA was used at 
pH 6.4, using the purified mini-Mab, 40% ofmini-Mab purification yield was obtained. 
PC Purification. PC purification using the pure sample was performed on mini-
Mab immobilized gel matrices. CNBr activated sepharose and monoaldehyde-agarose 
(Actigel™ ALD) matrices were tested. Immobilization efficiency showed approximately 
80 % and 45 % for the CNBr activated sepharose matrix and Actigel, respectively. PC 
purification efficiency using the CNBr activated sepharose and the Actigel showed 
approximately 6 % and 10 %, respectively. 
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Economic Analysis of PC Production. PC production cost using between mini-
Mab and Mab, Korah (2003) were compared in terms of the costs of antibody production, 
antibody purification, and PC purification. The specific production cost of mini-Mab was 
evaluated 500 times lower than that of Mab's. Based on mini-Mab purification using 
IMAC column, the yield ofMab purification (70 %) was evaluated 1.75 times higher than 
mini-Mab's (40 %; Korah, 2002). PC purification yield using Mab (70 %) was evaluated 
7 times higher than mini-Mab's (10%). Based on the date obtained from the antibody 
production, antibody purification, and PC purification, Korah estimated that PC 
purification using the mini-Mab is 40 times cheaper than using regular Mab. 
13 
CHAPTER III 
MATERIALS, INSTRUMENTS, AND METHODS 
A. MATERIALS 
1. Mini-Mab Production 
Thirteen recombinant E. coli HB2151 colonies that contain the PC mini-Mab 
producing gene were provided by Dr. Michael Sierks at the Arizona State University. 
The E. coli culture media was made using Trypton, NaCI, glucose, phenylmethylsulfonyl 
fluoride (PMSF), ampicillin (Sigma-Aldrich, Inc.; St. Louis, MO), and yeast extract 
(Bacto Laboratories; Liverpool, Australia). Isopropyl P-D-thiogalactopyranoside (IPTG; 
ICN Biomedical, Inc.; Irvine, CA) was added into the production media to induce the 
mini-Mab expression. Lactose was added (Sigma-Aldrich, Inc.) and sucrose, Triton X-
100, and phopholipase A2 (Sigma-Aldrich, Inc) for the study of mini-Mab release from 
E. coli cells. E. coli cells were separated by a centrifuge in centrifuge tubes (Greiner Bio-
one; Longwood, FL). The supernatant was concentrated using Centricon, a 19 ml 
ultrafiltration filter (Millipore; Schwalbach, Germany). 
2. Mini-Mab Purification 
Protein A immobilized CNBr-activated Sepharose™ CL-4B (Protein A 
Sepharose TM), glycine, and citric acid were purchased from Sigma-Aldrich. Glass 
Econo-Column® chromatography column (Bio-Rad; Hercules, CA) was used to pack the 
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gel matrix. Slide-A-Lyzer® Dialysis Cassette (Pierce; Rockford, IL) with 10,000 Da 
molecular weight cut off was used for the buffer dialysis. 
3. PC Purification 
PC and Cohn Fraction IV -1 paste were provided by the American Red Cross 
(Rockville, MD) and human blood factors II, VII, IX, and X were purchased from 
Innovative Research, Inc. (Southfield, MI). Normal hydroxysuccinimide (NHS)-
activated Sepharose ™ 4 Fast Flow (NHS Sepharose TM) and diethylaminoethyl (DEAE) 
Sepharose™ Fast Flow (DEAE Sepharose™) were purchased from Amersham 
Biosciences (Piscataway, NJ). Actigel ALDTM (ActigeI™) and Epoxy Activated 
Ultraflow 4™ (Epoxy Activated™) were from Sterogene (Carlsbad, CA). A Supor®, 
membrane filter papers with 47 mm diameter and 0.2, 0.45, and 0.8 /lm pore sizes were 
obtained from Gelman Sciences (Ann Arbor, MI) to filter buffer and Cohn paste solution. 
4. Gel Electrophoresis 
Tris base, lauryl sulfate, glycerol, bromophenol blue, methanol, Brilliant Blue R, 
acrylamide solution, ammonium persulfate, tetramethylethylenediamine (TEMED) and 
acetic acid (Sigma-Aldrich) were used for the sodium dodecyl sulphate polyacrylamide 
gel electrophoresis (SDS-PAGE). SigmaMarker™ standard molecular marker (Sigma-
Aldrich; myosin, 205 kDa; ~-galactosidase, 116 kDa; phosphorylase b, 97 kDa; fructose-
6-phosphate kinase, 84 kDa; bovine serum albumin, 66 kDa; glutamic dehydrogenase, 55 
kDa; ovalbumin, 45 kDa; glyceraldehyde-3-phosphate dehydrogenase, 36 kDa; carbonic 
anhydrase, 29 kDa; trypsinogen, 24 kDa; trypsin inhibitor, 20 kDa; a-lactalbumin, 14.2 
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kDa; and aprotinin, 6.5 kDa) was used for the comparison of the molecular weights of 
proteins on the SDS-PAGE. 
5. Enzyme Linked Immunosorbent Assay (ELISA) 
96 well microtiter plates (Nalgen Nunc International; Roskilde, Denmark) were 
used for ELISA for the measurement of the concentrations of the mini-Mab, PC, vitamin 
K dependent coagulation factors, and human serum albumin (HSA). 2-amino-2-
(hydroxymethyl)-1,3-propanediol (Tris base), NaHC03, Na2C03, phosphate buffered 
saline (PBS), Tween 20, horseradish peroxidase-conjugated goat anti mouse IgG, 0-
phenylenediamine dichloride (OPD) solution containing urea hydrogen peroxide, human 
serum albumin, and bovine serum albumin (BSA) were purchased from Sigma-Aldrich. 
For the mini-Mab ELISA, anti-c-myc antibody (9E10) was obtained from Santa Cruz 
Biotechnology (Santa Cruz, CA). For the ELISA of PC and the other factors, Rabbit 
polyclonal factor II antibody was purchased from Biomeda Corporation (Foster city, CA) 
and mouse monoclonal factor II antibody, from Enzyme Research Laboratories (South 
Bend, IN). Rabbit polyclonal factor VII antibody was obtained from Novus Biologicals, 
Inc. (Littleton, CO), and goat polyclonal factor X antibody and goat polyclonal human 
serum albumin antibody, from US biological (Swampscott, MA). Mouse monoclonal 
human serum albumin antibody was purchased from Biodesign International (Saco, ME). 
Rabbit polyclonal antibodies for PC and factor IX, mouse monoclonal antibodies against 
PC and factors VII, IX, and X were obtained from Sigma-Aldrich. 
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6. Protein Assay 
The total protein was quantified using Bicinchoninic Acid (BCA * TM) protein 
assay reagents from Pierce (Rockford, IL). 
All other chemicals, unless otherwise specified, were purchased from Sigma-
Aldrich. 
B. INSTRUMENTS 
1. Mini-Mab Production 
Antibodies, E. coli cell lines, and purified samples were stored in a -70°C freezer 
(Resco; Ontario, Canada). An autoclave (Sterilmatic; Market Froge; Everett, MA) was 
used to sterilize the media by heat or a disposable sterile syringe filter (Coming Glass 
Works; Coming, NY) was used to sterile the media. A laminar hood (Purifier Class II 
Biosafety Cabinet; Labconco Corporation; Kansas City, MO) was used for the control of 
contamination while the E. coli cells are inoculated in the media. E. coli was cultured in 
a shaking incubator (C24 incubator shaker; New Brunswick Scientific; Edison, NJ). 
Accumet pH Meter (Fischer Scientific; Pittsburgh, P A) was used to measure the pH. E. 
coli cell density and the protein concentration were measured using a DU SERIES 500 
Spectrophotometer (Beckman Instruments, Inc.; Fullerton, CA). The produced mini-Mab 
and the purified PC were quantified using an ELISA plate reader (Bio-Rad; Hercules, 
CA). The incubation temperature for protein quantification and ELISA was controlled in 
Isotemp Incubator (Fischer Scientific). 
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2. Mini-Mab and PC Purification 
A Marathon 3200 ® general-purpose centrifuge (Fischer Scientific) was used for 
E. coli cell separation and the ultra-filtration. The purification of the mini-Mab and PC is 
performed using FRAC-100 (Amersham Biosciences; Piscataway, NJ) and its 
accessories, peristaltic pump P-1, Control Unit UV -1, Optical Unit UV -1, and the 
recorder REC 101. Chromatography columns were purchased from Bio-Rad (Hercules, 
CA). SDS-PAGE was carried out using a Mini-Protean 3 Celli PowerPac Basic System 
(Bio-Rad) and its accessories, combs, plates, and casting accessories for 10-well. 
C.METHODS 
1. Mini-Mab Production 
Culture media for the E. coli cell growth and mini-Mab production were prepared. 
2XTY media (Trypton: 16 gil; yeast extract: 10 gil; NaCl: 5 gil) was autoclaved at 121°C 
for 20 minutes. Glucose stock solution at a concentration of 200 gil was filtered using 
syringe filters of 0.45 ~m pore size (Coming Glass Works; Coming, NY), and applied to 
a flask to adjust the final concentration of 1 % for the cell growth media and 0.1 % for the 
mini-Mab production media. Ampicillin stock solution at a concentration of 100 mglml 
was applied to the media to make the final concentration of 1 00 ~g/ml. 
The compositions of the cell growth and the mini-Mab production media are as 
follows: 
(1) Cell growth media: 2XTY media, 1 % glucose, and 1 00 ~g/ml of ampicillin. 
(2) Mini-Mab production media: 2XTY media, 0.1 % glucose, 1 00 ~g/ml of ampicillin, 
and 1 mM oflPTG. 
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E. coli colonies from the cell stock were added to the cell growth media and 
cultured at 37°C in a shaking incubator at 300 rpm. When the optical density (O.D.) of 
the culture media reached 0.9 at the wavelength of 600 nm, the cells were separated using 
a centrifuge at 4000 rpm for 20 minutes. The separated cells from the cell growth media 
were transferred to the mini-Mab production media and cultured in the shaking incubator 
at 300 rpm for 24 hrs at 30°C. After the mini-Mab production, cells were separated 
using the centrifuge at 4000 rpm for 20 minutes. The concentration of mini-Mab in the 
supernatant is measured using ELISA. To make the E. coli cell stock, E. coli cells were 
grown in the cell growth media until the optical density (O.D.) of the media becomes 0.9, 
and the E. coli cells were separated using the centrifuge at 4000 rpm for 20 minutes. The 
separated cells were transferred to 20% glycerol solution in the laminar hood and stored 
in a deep freezer (-70°C). Whenever needed, the E. coli cell stock was thawed and 
inoculated to the media in the laminar hood. 
2. Mini-Mab Purification 
The mini-Mab in the production media supernatant was purified using Protein A 
Sepharose ™ following the manufacturer's instruction. Protein A Sepharose ™ matrix 
was suspended with 0.02 M NaHzP04-0.15 M NaCl solution (PH 8.0) overnight at 4°C to 
swell. The matrix was degassed using vacuum pump for an hour at 200 mm Hg. The 
matrix suspension was transferred into a chromatography column and was allowed to 
settle for an hour. Then, it was washed with 20-bed volumes of 0.02 M NaHzP04-0.15 M 
NaCl solution. 
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After the protein A column is prepared, the supernatant from the production 
media was applied into the column at the linear velocity of 0.015 cm/s. After the 
adsorption process is completed, any unbound protein was washed using 0.02 M 
NaHzP04-O.15 M NaCl solutions until the UV reading reached the base line. The bound 
mini-Mab was eluted with 0.1 M glycine buffer (pH 3.0) or 0.1 M citric acid buffer (pH 
3.0). Fractions were collected, and neutralized with 0.1 M NaOH. The column was 
washed with 20-bed volume of 0.02 M NaHzP04-O.15 M NaCl solution following 0.5 M 
NaCl solution. The column was re-equilibrated with 20-bed volume of 0.02 M 
NaHzP04-O.15 M NaCl solutions for the next use. The amounts of the mini-Mab in the 
supernatant, eluted fractions, and other solutions were measured using ELISA. 
3. PC Purification 
Actigel ALDTM matrix. Mini-Mab coupled Actigel™ matrix was prepared 
following the manufacturer's instruction. Approximately 1 ml of the matrix was applied 
to a sintered glass filter and washed with 3-bed volumes of 0.1 M PBS buffer (coupling 
buffer; pH 6.9). The gels were suspended with 1 ml of the coupling buffer. 
Predetermined amount of the mini-Mab in coupling buffer was added to the gel 
suspension. 1 M NaCNBH3 (coupling solution) was added to the gel suspension and 
mini-Mab mixture at the final concentration of 0.1 M. The total volume of the mixture 
was adjusted to 3.5 ml with 0.1 M PBS buffer. The coupling reaction was performed by 
a shaking incubator at 100 rpm and 30°C for 5 hours. After coupling, the supernatant 
was removed using a sintered glass filter with 150 micron of pore size. 
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The matrix was washed with 3 bed-volume of adsorption/washing buffer (0.02 M 
sodium citrate-0.08 M NaCI at pH 6.0) following washing with 10-bed volume of 0.5 M 
of NaCI to remove non-covalently bound mini-Mab from the matrix. The filtrate was 
used to calculate the coupling yield. It was then degassed under vacuum for an hour at 
200 mm Hg. The gels were packed in a column. The matrix was equilibrated with lO-
bed volume of 0.02 M sodium citrate-0.08 M NaCI (pH 6.0). 
0.02 M sodium citrate-0.08 M NaCI at pH 6.0 (adsorption/washing buffer) and 0.1 
M sodium carbonate buffer-O.l5 M NaCI at pH 10.0 (elution buffer) were chosen for PC 
purification following the PC purification protocol of Kang, et al. (1992). When the 
column for the PC purification was ready, 20 ~g of pure PC was applied to the column. 
10 minutes was allowed for satisfactory adsorption reaction. The column was then 
washed withl0-bed volume of adsorption/washing buffer at the linear velocity, 0.015 
cm/s. After the washing was complete, the elution buffer was applied at the velocity of 
0.015 cm/s until the UV reading returned to the base line. The pH of the eluted PC was 
immediately neutralized by adding 3.0 M HCl. The column was then washed with the 
10-bed volume of adsorption/washing buffer and 0.5 M NaCl following the 10-bed 
volume of adsorption/washing buffer. 
NHS-activated Sepharose™ 4 Fast Flow. Coupling of the mini-Mab was 
performed by the manufacturer's instruction. 1 ml ofNHS-activated Sepharose™ 4 Fast 
Flow (NHS Sepharose TM) matrix was washed on a sintered glass filter with 10 ml of 1 
mM HCI at 4°C. The matrix was suspended in 10 ml of 0.2 M NaHC03-O.5M NaCI (PH 
8.2; coupling buffer). Immediately afterwards, predetermined amount of the purified 
mini-Mab was added to the matrix suspension. The total mixture volume was adjusted to 
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6 ml. Incubation was performed by a shaking incubator at 100 rpm and 30 °c, for 5 
hours. After coupling, the supernatant was removed and 6 ml of 0.1 M Tris-HCI (pH 8.0; 
blocking buffer) was added to the matrix, was reacted for additional 4 hours at room 
temperature. The matrix was packed in a chromatography column. To remove the non-
covalently bound mini-Mab, the gel in the column was washed with 25-bed volumes of 
each PBS buffer (PH 7.3), PBS-l M NaCI, cold water, 0.1 M Na2C03-0.5 M NaCI (pH 
11), 0.1 M sodium acetate (0.5 M NaCI; pH 4), 0.1 M Na2C03-0.5 M NaCI (PH 11), 0.1 
M sodium acetate (0.5 M NaCl; pH 4) and again PBS respectively. The mini-Mab 
amount in the filtrate was quantified by ELISA to obtain the coupling efficiency. 
Epoxy Activated Ultraflow™. Mini-Mab coupled Epoxy Activated Ultraflow™ 
matrix was prepared following the manufacturer's instruction. Approximately 1 ml of 
the gel matrix was applied to a sintered glass filter and washed with 5 ml of deionized 
(DI) water. Predetermined amount of the mini-Mab was dissolved in 2 ml of 0.1 M 
sodium phosphate buffer (pH 10; coupling buffer). The pre-washed matrix was added to 
the mini-Mab solution. The solution of the matrix and mini-Mab was mixed in a shaking 
incubator at 100 rpm and 25°C, for 18 hours. After coupling, the supernatant was 
removed and 1.5 ml of 50 mM of ethanolamine (pH 8.5; blocking buffer) was added to 
the complex of the mini-Mab and the matrix and reacted for additional 4 hours at room 
temperature. To remove the non-covalently bound mini-Mab, the gel in the column was 
washed with 25-bed volumes of DI water and 3-bed volumes of adsorption/washing 
buffer (0.02 M sodium citrate-0.08 M NaCI at pH 6.0) following washing with la-bed 




ELISA for the mini-Mab guantification. The ELISA protocol was originally 
developed by Wu, et al. (1998) and optimized by Korah, et al. (2003). 
The washing buffer used for this assay is phosphate buffered saline with 0.05% 
Tween 20 (PBST, 0.01 M PBS, 0.138 M NaCI, 0.0027 M KCI, pH 7.4), 
dilution/adsorption buffer was PBS, and the blocking buffer was PBST with 1 % BSA. 
(1) Coat each well of a 96 well plate with 1 00 ~l of PC at a concentration of 1 ~g/ml in 
adsorption buffer except the first column (control). 
(2) Incubate the plate overnight at 4 DC. 
(3) Wash each well with the PBS buffer (250 ~l/well) three times. 
(4) Apply the blocking buffer (250 ~l/well) in each well and incubate the plate for 90 
minutes at room temperature. 
(5) Wash each well with the washing buffer three times. 
(6) Apply 1 00 ~l of the dilution buffer to all wells except the wells on the first (control) 
and the second columns. Apply 200 ~l of the mini-Mab standard, as well as the 
samples, to the respective rows in the second column and perform a liz serial dilution. 
(7) Incubate the plate at room temperature for two hours. 
(8) Wash each well with the washing buffer three times. 
(9) Apply 100 ~l/well of 9E 1 0 antibody at a concentration of 1 ~g/ml in PBS to all wells 
except first column. 
(10) Incubate the plate for two hours at room temperature. 
(11) Wash each well with the washing buffer three times. 
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(12) Prepare horseradish peroxidase (HRP) conjugated goat anti-mouse IgG at a 1: 1000 
dilution in PBS and add 1 00 ~l/well. 
(13) Incubate the plate for 30 minutes at room temperature. 
(14) Wash each well with each washing buffer and PBS three times respectively. 
(15) Add 1 00 ~l/well of OPD solution. 
(16) Incubate the plate in a dark room for 30 minutes at room temperature. 
(17) Read the absorption of the wells at 450 nm using the ELISA plate reader. Calculate 
the concentration of the mini-Mab in the sample using the standard. 
ELISA for quantification of PC and other factors. ELISA was based on the 
protocol developed by many researchers (Boyer, et aI., 1984; Soria, et aI., 1985; Suzuki, 
et aI., 1985) and this ELISA protocol was optimized by the American Red Cross (Wu, 
2000b). 
The washing buffer used for this assay is Tris buffered saline (TBS, 12.5 mM Tris 
buffer, 0.05 M NaCl, pH 7.2) with 0.05% Tween 20 (TBST), dilution buffer was TBS, 
and the blocking buffer was TBS with 0.1 % BSA for the PC and other factors or 4 % fish 
serum for human serum albumin. Buffer for adsorption on the wells was 0.1 M 
NaHC03/Na2C03 at pH 9.6. 
(1) Coat the wells with 1 00 ~l of the polyclonal antibody against the factor in the 
adsorption buffer at the concentration of 2 ~g/mI. 
(2) Incubate the plate overnight at 4°C. 
(3) Wash each well with the washing buffer (250 ~l/well) three times. 
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(4) Block each well with the blocking buffer (250 Ill/well) for 90 minutes at 37°C in an 
incubator. 
(5) Wash each well with the washing buffer three times. 
(6) Apply 100 JlI of the dilution buffer to all wells except the wells on the first (control) 
and the second columns. Apply 200 III of PC or other factors as standard, as well 
as the samples, to the respective rows in the second column and perform ~ serial 
dilutions. 
(7) Incubate the samples at 37°C in an incubator for 90 minutes. 
(8) Wash each well with the washing buffer three times. 
(9) Apply 100 Ill/well of the mouse monoclonal antibody for the respective factor at a 
concentration of 1 Ilg/ml. 
(10) Incubate the plate for 90 minutes in an incubator at 37°C. 
(11) Wash each well with the washing buffer three times. 
(12) Prepare goat anti-mouse IgG peroxidase conjugate at a 1: 1000 dilution in the 
dilution buffer and add 100 Ill/well. 
(13) Incubate the plate at room temperature for 30 minutes. 
(14) Wash each well with the washing buffer at least six times. 
(15) Add 100 Ill/well of the OPD solution. 
(16) Incubate the plate in a dark room at room temperature for 30 minutes. 
(17) Read the absorption of wells at 450 nm using an ELISA plate reader. Obtain the 
concentration of PC or other factors in the sample using the standard. 
25 
5. Protein Assay 
Bicinchoninic Acid (BCA * TM) protein assay was used to quantify the total protein 
in the sample. A 100 /-!l of protein sample was added to 2 ml of the BCA * ™ Protein 
Assay Reagent. The solution was mixed and was incubated at 37°C for 30 minutes. 
After the incubation, the solution was cooled to room temperature for an hour, and the 
absorbance was measured at 562 nm. From the optical density of the sample, the 
concentration of protein was calculated using BSA as a standard. 
Purified mini-Mab can be optically quantified using a spectrophotometer reading 
O.D. at 280 nm. The extinction coefficient of variable light chain of human 
Immunoglobulin G (IgG) was known to be E~81~m=1.16 (Fasman, 1989) but the 
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Figure 3. Standard curve for the purified mini-Mab concentration. BSA 
was used as a reference material for BCA protein assay. The incubation 
temperature and time were 37 DC and 30 minutes respectively. 
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Therefore, the amount of the mini-Mab by the BCA * ™ was correlated with the 
spectrophotometer reading at 280 for the purified mini-Mab (Figure 3). The extinction 
coefficient of the mini-Mab was estimated as E ~l~m =0.94. 
6. SDS-PAGE 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-P AGE) was 
performed following the manufacturer's instruction. The separation gel was made with 
30% acrylamide solution, 20% ammonium per sulfate, water, TEMED, and Tris HCl 
buffer at pH 8.8. The protein was denatured in SDS solution at 100°C for 5 minutes. 
Once the gel is ready, the 20 III of each sample and the molecular marker were applied to 
wells respectively. The amount of protein sample in each well was at least 1 Ilg. The 
molecular weight was obtained by comparing the positions of the molecular markers that 
shows bands of known molecular weight. 
7. Pretreatment of Cohn Fraction IV -1 for the PC Purification 
The preparation of Cohn Fraction IV -1 sample was carried out based on the 
protocol by Wu (2000) with the modifications of the centrifugation speed using 4000 rpm 
instead of using 8000 rpm and dilution ratio of Cohn paste to buffer at 1 to 20 instead of 
at 1 to 30. The Cohn paste was dissolved in sodium citrate buffer (PH 6.0) at a ratio of 1 
to 20 (weight to volume ratio) at 4 °c for 5 hours with constant stirring using a magnetic 
stirrer. Then the solution was centrifuged at 4000 rpm for 20 minutes and the supernatant 
was filtered using three filters with different pore sizes, such as, 0.8, 0.45, and 0.2 11m, 
respectively, which were found to be effective to filter the Cohn Fraction IV -1 solution 
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by Lee in our lab. The filtrate was used as the source material for the PC purification 
using the mini-Mab. 
8. Ion Exchange Chromatography of Cohn Fraction IV-l Using DEAE Sepharose™ Fast 
Flow 
Following the manufacturer's instruction, DEAE Sepharose™ Fast Flow (DEAE 
Sepharose TM) matrix was prepared. Approximately 1 ml of the gel matrix was applied to 
a sintered glass filter and washed with 5 ml of deionized (DI) water and degassed for one 
hour, and packed in a chromatography column. Then, the matrix was equilibrated with 
IO-bed volumes of 25 mM sodium citrate buffer (pH 6.0). Approximately 20 g of Cohn 
Fraction IV -1 was dissolved into 400 ml of 0.02 M sodium citrate buffer at pH 6.8 at 4 °c 
with magnetic stirring for approximately three hours. The Cohn Fraction IV -1 solution 
was then centrifuged at 4000 rpm for 20 minutes. The supernatant was adjusted to pH 
6.0 and then applied to the DEAE Sepharose ™ at a flow rate of 0.004 cm/s. The column 
was then washed with 0.025 M sodium citrate buffer (pH 6.0) using 50-bed volumes. 
The column was then washed with 20 column volumes of 0.02 M 4-morpholineethane-
sulfonic acid (Mes) including 0.17 M NaCI (pH 6.0) using about I50-bed volumes. 
Then, the fractions were eluted by 3- to 4-bed volumes of elution buffer including 0.02 M 
Mes and 0.37 M NaCI at pH 6.0. For the matrix regeneration, 0.02 M Mes including 2 M 
NaCI at pH 6.0 was used. 
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CHAPTER IV 
RESUL TS AND DISCUSSION 
Three main studies performed were: optimization of PC mini-Mab production 
condition; mini-Mab purification using protein A Sepharose; and PC purification from 
Cohn Fraction IV -1 using the purified mini-Mab. Experimental results presented in this 
dissertation are from at least two sets of experiments, unless specified otherwise. 
A. PROCESS OPTIMIZATION OF THE MINI-MAB PRODUCTION 
1. Selection ofthe Highest Mini-Mab Producing E. coli Colony 
To produce the mini-Mab using E. coli, there are two stages of bioprocesses: a 
stage of E. coli growth and then a stage of the mini-Mab production by the E. coli. 
The original protocol for the mini-Mab production, which was provided by 
Sierks, was with 2XTY media including 1 % of glucose; at 37°C; and at a rate of shaking 
300 rpm for the growth of the colony and with 2XTY media including 1 mM of IPTG, 1 
mM PMSF, and 0.1 % of glucose; at 30°C; at a rate of shaking 300 rpm; and for 24 hours 
of the production time for the mini-Mab production (Wu, et aI., 1998b). 
Thirteen E. coli colonies producing mini-Mab against PC, A2FX, A3FX, A4FX, 
C1FX, C7FIX, E4FX, E6FIX, E7FIX, E10FIX, G3FX, H3FX, H3FIX, and H12FIX were 
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Figure 4. Mini-Mab production levels by thirteen E. coli colonies. 
[Experimental conditions: 30°C, initial pH 7.0, and 0.1 % glucose] 
After the completion of the production, the amount of the mini-Mab in the 
supernatant was quantified by ELISA (Figure 4). Among 13 colonies, E4FX, E7FIX, and 
H3FIX colonies produced much more than others, approximately 1 0 ~ 15 ~g/ml of the 
mini-Mab in the supernatant. The production by E4FX was the greatest and was selected 
for further studies. 
2. Glucose Concentration 
Since the mini-Mab IS produced using lac operon in E. coli cells, high 
concentration of glucose in the production medium inhibits the mini-Mab production by 
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Figure 5. The effect of glucose concentration on mini-Mab production. 
[Experimental conditions: 30°C and initial pH 7.0] 
concentration in the production media on the mini-Mab production was examined at 
various glucose concentrations, while other media composition remained constant (Figure 
5). 
When the glucose was not added to the production media, mini-Mab production 
was 272 /-Lg/ml. The mini-Mab production level was the highest (320 /-Lg/ml) at a glucose 
concentration of 0.1 %. The mini-Mab production appeared to be associated with the cell 
growth in the production medium because the final cell density for the medium with 0.1 
% glucose was approximately 3 times higher than that for the medium without glucose. 
At a concentration of 1 % and when the medium was not changed from the growth 
medium to the production medium, there was no mini-Mab production. At a high 
glucose concentration, acetate may have been formed and inhibited the mini-Mab 
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production (Imanaka, et aI., 1973). The glucose concentration at 0.1 % was kept for our 
further studies, as in the original protocol. 
3. Optimal Times for the Cell Growth and for Mini-Mab Harvest 
Optimal Time for the Completion of Cell Growth. At the end of the first stage, 
when the medium optical density (O.D.) becomes 0.9, cells are separated from the growth 
medium and transferred to the mini-Mab production medium. In order to accurately 
predict the time for the completion of the cell growth without frequently measuring the 
optical density of the growth medium, the growth of E4FX was observed with respect the 
time. 
As can be seen in Figure 6, the lag phase lasted for hours. Then during the 
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Figure 6. Cell growth curve of E. coli HB2151 E4FX. [Experimental 
conditions: 35°C and 1 % glucose] 
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The time to reach the O.D. of 0.9 after the cell inoculation was approximately 5 hours 
and 30 minutes with very little deviation. 
Optimal Production Time. In the original protocol, the time for completing mini-
Mab production after adding the inducer IPTG was 24 hours. To obtain the optimal time 
for the mini-Mab harvest, the concentration of the mini-Mab in the medium was 
measured in time (Figure 7). Over the initial five hours, very little mini-Mab was 
produced. Then from 5 to 15 hours, the mini-Mab production was almost linear with 
time and the production was complete at the time of 18 hours. After 18 hours, the 
amount of the mini-Mab decreased, showing possible mini-Mab degradation by protease 
in the medium. Therefore, 18 hours after adding IPTG, was selected as our optimal mini-
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Figure 7. Mini-Mab production time after adding oflPTG. [Experimental 
condition: 30°C, initial pH 7.0, and 0.1 % glucose] 
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4. Effect of the Production Medium pH on the Mini-Mab Production 
The pH in the growth medium at O.D. 0.9 is approximately 6, the initial pH of the 
mini-Mab production medium is 7, and the pH of the production medium after 
completing the mini-Mab production is 9. Since there are significant changes in the 
media pHs at the end of the cell growth, at the beginning and at the end of the mini-Mab 
production, the effect of initial pH on the mini-Mab production was investigated. 
The initial pH of the production medium was adjusted at various pHs between 5 
and 9 and the mini-Mab production was quantified (Figure 8). The final pH for the one 
starting at pH 5.0 was 5.3 and no mini-Mab production was observed. The final 
























Figure 8. The effect of initial pH of the production media on the mini-Mab 
production. [Experimental condition: 18 hours of production time, 30°C, and 
0.1 % glucose] 
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production levels at the initial pH 5.5 and 6 were similar and the greatest. For ones at pH 
higher than 6, production decreased as pH increases. At the pH 9, the production is only 
1/3 of that of the pH 5.5 or 6.0. The pH between 5.5 and 6.0 was decided to be the 
optimal initial pH for mini-Mab production. 
5. Temperature 
It was reported that the production of the mini-Mab produced by phage display 
method is affected by temperature (Kempf, et aI., 2001). The effect of temperature on the 
mini-Mab production was, therefore, investigated in a temperature range of 23-35 °C 
(Figure 9). 






























Figure 9. The effect of temperature on mini-Mab production. [Experimental 
condition: 18 hours of production time, initial pH 7.0, and 0.1 % glucose] 
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The production at temperature up to 30°C showed a constant level of around 320 
)..lg/ml. The production level at 33°C was significantly low, and at 35 °c, the production 
was almost zero. The results show that the production is stable at a reasonable room 
temperature as long as the temperature is below 30°C. 
6. IPTG Concentration 
The most expensive component of the production medium is the inducer, 
isopropyl P-D-thiogalactopyranoside (IPTG). The IPTG concentration used in the 
original protocol was 1 mM (Wu, et aI., 1998). The study performed by Korah, et al. 
(2003b) showed that when IPTG was used at a level of 1 mM, its cost becomes 25 % of 
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Figure 10. The effect of IPTG concentration on mini-Mab production. 
[Experimental condition: 18 hours of production time, 30°C, and 0.1 % 
glucose] 
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Korah, et al. (2003b). It was found that the production rate of mini-Mab was the greatest 
at 0.1 and 1 mM of IPTG. 
Here, the mini-Mab production between at 0.1 and 1 mM of IPTG was 
investigated. The results (Figure 10) showed that the production levels of the mini-Mab 
at 0.1, 0.5, and 1 mM IPTG concentrations were almost the same. Therefore, the 
optimum concentration of IPTG was confirmed to be 0.1 mM. 
7. Lactose as an Inducer 
Kilikian, et al. (2000) reported that lactose may be used as an inducer for 
recombinant intracellular protein production. The amount of the chicken muscle 
Troponin C produced by the recombinant E. coli using lactose as an inducer (96 mg/g-dry 
















0.1 mM IPTG 40 mM Lactose 70 mM Lactose 97 mM Lactose 
Figure 11. The effect of lactose as an inducer on mini-Mab production. 
[Experimental condition: 18 hours of production time, 30°C, and 0.1 % 
glucose] 
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Since lactose is approximately 1 % of the cost of IPTG, lactose at three different 
concentrations, 15 (40 mM), 25 (70 mM), and 35 giL (97 mM) fallowing the 
concentrations used by Kilikian, et al. (2000) were tested (Figure 11). Very little mini-
Mab was produced at all three lactose concentrations and it was concluded that lactose 
was not proper as an inducer for the mini-Mab production. 
8. Mini-Mab Release from E. coli Cells 
The mini-Mab developed by Dr. Michael Sierks at Arizona State University was 
designed to release mini-Mab outside of E. coli cells (Wu, et aI., 1998a). However, the 
actual mini-Mab release status was not confirmed. Korah (2002) has previously tested 
the release of mini-Mabs in the E. coli cells by loosing cell membranes using 
ultrasonication and found that ultrasound denatured the mini-Mab, indicating that the 
mini-Mab is pressure sensitive. 
Sucrose. There have been reports that a high level expression of mini-Mabs in E. 
coli often results in aggregation after their transport to the periplasm (Whitlow and 
Filpula, 1991; Kipriyanov, et aI., 1994). Kipriyanov, et aI. (1997) also reported that 
sucrose at 0.4 M helped the aggregated mini-Mab secrete outside of E. coli because 
sucrose is small enough to diffuse into the periplasmic space of E. coli but not 
metabolized. Therefore, the sucrose effect on the PC mini-Mab release was tested. The 
production medium was prepared with and without sucrose. The mini-Mab production 
was performed. Mini-Mab concentrations in the medium were measured after the 
completion of the mini-Mab production (Figure 12). The mini-Mab concentration in the 
medium with sucrose was 20 % lower than that without sucrose. 
38 
250r-----------------------------------------~ 















Sucrose concentration (M) 
Figure 12. The effect of sucrose on the mini-Mab release. [Experimental 
condition: 18 hours of production time, 30°C, and 0.1 % glucose] 
Detergent and Membrane Reactive Cationic Peptides. There have been studies on 
the release ofthe recombinant proteins from the periplasm using non-ionic detergents and 
cationic peptides, such as, tetraethyleneglycolmonodecyl-ether, Triton X-IOO, and 
phospholipase A2 (Morbe, et ai., 1997). The outer membrane of gram-negative bacteria 
is impermeable to macromolecules. Only some hydrophobic molecules, such as non-
ionic detergents, may diffuse through the lipopolysaccharide (LPS), which is a major 
component of membranes (Nikaido, 1990). Cationic substances, such as cationic 
peptides, bind to the LPS containing membranes because of the polyanionic nature of the 
membrane, leading the membrane permeable (David, et ai., 1996). 
Therefore, in this study, two reagents, phospholipase A2 in PBS and Triton X-100 
were tested in PBS buffer. 
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After 18 hours mini-Mab production, the cells were separated using the centrifuge 
at 4,000 rpm for 20 minutes, washed with PBS buffer, and re-suspended in 5 ml of PBS 
buffer. The permeabilizing agents were added to the cell-containing buffer at a final 
concentration of 0.4 /-lg/ml for phopholipase A2 and 2 % for Triton X-IOO. PBS buffer 
was used as a control. 
After 40 minutes of reaction, the cells were separated by centrifugation at 4,000 
rpm for 20 minutes, and the mini-Mab in the supernatant was quantified by ELISA 
(Table 2). In the PBS buffer (control), approximately 50 /-lg of mini-Mab was measured 
and in phospholipase A2 showed less mini-Mab release. When triton X-I 00 was used, no 
mini-Mab was detected by ELISA. 
Therefore, it is concluded that most of the mini-Mab produced by E. coli is 
released outside of the cell or the reagents tested are not effective on releasing the mini-
Mab from the cell. 
Table 2. The effect of a membrane reactive cationic peptide (phospholipase A2) 
and a detergent (Triton X-IOO) on the mini-Mab release from the cell. 
[Experimental condition: a final concentration of 0.4 /-lg/ml for phopholipase A2 
and 2% for Triton X-IOO] 
Total mini-Mab release 
detected by ELISA ()lg) 
PBS buffer (control) 51.2±2.1 
Phospholipase A2 17.5±0.05 
Triton-l 00 -
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9. Effects of PM SF on Mini-Mab Production and Storage 
In the original protocol of the PC mini-Mab production, 1 mM of PMSF was 
added in the production medium (Wu, et aI., 1998). Mini-Mabs have been reported to be 
degraded by the proteases in the medium and a serine protease inhibitor PMSF has been 
frequently added in the production medium to inhibit the protease activity (Whitlow, et 
aI., 1993). It was also reported that PMSF improved the antibody stability during storage 
at 4 °c (Brichta, et aI., 2003). PM SF is, however, toxic in human body by inhibiting the 
serine protease (Bollen, et aI., 1988). Here, the effects of PM SF on the mini-Mab 
production and on preventing the mini-Mab from being degraded during storage were 
investigated. 
PMSF was added to the production medium at a concentration of 0, 0.1, or 1 mM 
and the production was preceded. At the end of the production, the amount of the mini-
Mab in the supernatant was quantified by ELISA (Table 3). The mini-Mab production 
decreased with the increase in PMSF concentration. At the PM SF concentration of I 
mM, the production level was only 60 % of the one with no PMSF. When the mini-Mab 
production was studied per unit dry cell weight, the mini-Mab production levels for both 
with and without PMSF were approximately the same, i.e. 90 mg/g-dry cell weight. 
Table 3. The effect of PM SF on the mini-Mab production. [Experimental 
condition: 0.1 mM of IPTG concentration, initial pH 6.0, and 18 hours of 
production time] 
PM SF Mini-Mab concentration (Ilg/ml) 
Mini-Mab production 
per cell weight (mg/g) 
No PMSF 560±35 90.0±16 
0.1 mM 430±88 90.1±18 
ImM 350±74 90.0±19 
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However, the total cell mass for the medium with 1 mM of PMSF was approximately 40 
% less than that without it, showing possible cell growth inhibition by PMSF. 
The effect of PMSF on the mini-Mab degradation during the mini-Mab storage 
was also studied. The culture broth was divided into six portions: Two were stored in 
-70 DC without PMSF, with or without cells for 12 days; two were stored at 4 DC with 3 
mM of PMSF, with or without cells for 9 days; the other two were stored at 4 DC without 
PMSF, with or without cells for 9 days. After the storage, the mini-Mab in the medium 
was quantified by ELISA (Table 4). When the culture broth was stored at -70 DC, the 
mini-Mab was kept well with no activity reduction for both with and without cells. At 4 
DC, even with PMSF, there was significant degradation (> 22%). In the medium without 
PM SF , there was 10 - 16% more degradation than that with PM SF . When cells were 
present in the medium, the degradation was approximately 15 % more than without cells. 
From the study result, it is concluded that the best way of storing the mini-Mab produced 
medium is storing at -70 Dc. If the medium has to be stored at 4 DC for some reason, the 
cells should be removed first and stored with PMSF. 
Table 4. The effect of PM SF on the mini-Mab storage. 
Storage temperature Storage conditions 
Mini-Mab concentration 
(ggIml) 
Initial Concentration 351±35 
- 70°C (12 days) wlo PMSF, wi and wlo cells 351±16 
wi PMSF, wi cells 211±15 
4°C 
wi PMSF, wlo cells 274±12 
(9 days) 
wlo PMSF, wi cells 153±28 
w/o PMSF, wlo cells 240±45 
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B. MINI-MAB PURIFICATION 
1. Mini-Mab Purification Using Protein A 
Protein A is a cell wall protein of Staphylococcus aureus and has affinity to the 
VH domain of a mini-Mab (Akerstrom, et al., 1994; Wilkinson, 2000). Korah (2002) 
previously reported 18 % of PC mini-Mab purification yield using the protein A 
immobilized CNBr-activate Sepharose™ at a elution buffer pH 3.0. For the matrix 
preparation, she immobilized 0.45 g of protein A for 1 ml of CNBr Sepharose TM. In this 
study, the mini-Mab was purified by a commercially available protein A immobilized 
CNBr-activated Sepharose™ CL-4B matrix (protein A Sepharose™). The 
manufacturer's specification states that approximately 2 mg of protein A can be 
immobilized per 1 ml gel of the CNBr-activated Sepharose™ CL-4B. 100 ml of mini-
Mab containing supernatant at a mini-Mab concentration of approximately 450 /-tg/ml 
was applied to a column containing 1 ml of protein A Sepharose TM. After the adsorption 
and washing steps, the glycine buffer of pH 3.0 (Korah, 2002) was applied to elute the 
adsorbed mini-Mab. The amount of mini-Mab in the eluate was quantified by ELISA. 
The purification yield [(mini-Mab mass in the eluate)/(mini-Mab mass in the applied 
supernatant) x 100] was 35 % (Table 5). 
Table 5. Mini-Mab purification by Protein A Sepharose™. [Experiment 
conditions: 1 ml of gel matrix and 0.015 cm/s oflinear velocity] 
Elution buffer pH Yield ofmini-Mab purification (%) 
Glycine 3 35±1.4 
Citric acid 3 34±1 
43 
For the PC purification, the purified PC mini-Mab needs to be immobilized on the 
affinity gel matrices. The glycine buffer (linear structure formula: NH2-CH2-COOH) 
used for the mini -Mab purification has a NH2 residue and the residue was found to 
compete with the mini-Mab during the immobilization of the mini-Mab on the matrix. 
Therefore, another buffer that does not interfere the immobilization efficiency was 
explored. Citric acid [CH2(COOH)-COH(COOH)-CH2(COOH)] buffer was investigated 
at the elution pH of 3.0. For the purpose of mini-Mab purification, three different pHs of 
the elution were tested. Table 5 shows the purification yields of mini-Mab eluates by 
glycine and citric acid buffers. The yield of the mini-Mab eluted by citric acid buffer was 
34 %, which is similar to that by glycine buffer. For further studies, citric acid was used 
for the mini-Mab elution. 
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Figure 13. Electrophoresis of the samples of the mini-Mab purification from the 
production supernatant on Protein A Sepharose ™ 
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Various fractions from the mini-Mab purification process were analyzed by gel 
electrophoresis under non-reduced conditions (Figure 13). The result showed a single 
band around 30 kDa of the molecular weight, indicating that the eluate contains only the 
mini-Mab. 
C. PC PURIFICATION 
1. Cross reactivity of mini-Mab against PC and PC homologues 
Using the purified mini-Mab, the cross reactivity against PC and PC homologues 
was investigated by ELISA. The mini-Mab at a concentration of 2 ~g/ml was applied on 
each well of ELISA plate and each 1 ~g/ml of PC and PC homologues was adsorbed on 
the mini-Mab and 1 ~g/ml of each monoclonal antibody against the PC and PC 
homologues were applied to the adsorbed PC and PC homologues. 
0.4 
E 0.3 ,..-r-
~ f 02 ,..-r-
11 
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PC FII FVII FIX FX 
PC and PC-homologues 
Figure 14. Cross reactivity ofmini-Mab against PC and PC homologues. 
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The optical density (O.D.) of the developed color in ELISA wells were measured 
at a wavelength of 450 nm (Figure 14). The optical densities generated by factors II, VII, 
and X were minimal, indicating that the mini-Mab has little cross reactivity against the 
factors II, VII, and X. However, factor IX showed 1.5 times higher O.D. of PC. 
2. Selection of Gel Matrices 
When a biomolecule is covalently immobilized on matrix, the length of the spacer 
arm on the matrix may affect the activity of the immobilized biomolecule (Kang, et aI., 
1992). To study the effect of spacer arm length on PC purification performance of gel 
matrices, commercially available, four gel matrices with various lengths of the spacer 
arm were selected. They are CNBr Sepharose™, Actigel™, NHS Sepharose™, and 
Epoxy-activated™ CNBr Sepharose™ is 4 % agarose and reacts with amine residues of 
ligands for immobilization via one oxygen atom spacer (Eq. 1; Amersham Biosciences). 
Matrix-OCN(OH) + H,N-mini-Mab --> matrix-O(O)C~N-mini-Mab + NH40H (1) 
Actigel™ is 4 % cross-linked agarose and its monoaldehyde group reacts with amine 
residues of proteins, via 5-atom spacers (Eq. 2; Sterogene Bioseparations). 
Matrix-5 atom spacer-CHO + H2N-mini-Mab + reducing agent (NaCNBH3) 
--> Matrix-5 atom spacer-CH2-NH-mini-Mab + H20 (2) 
NHS Sepharose ™ is 4 % cross-linked agarose and has 6-amino-hexanoic acid forming 
10-atom spacers of oxygen and carbon. The terminal carboxyl group is activated by 
esterification with N-hydroxysuccinimide (NHS) and the amino group of the mini-Mab 
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couples to this active ester to form a stable amide linkage (Eq. 3; van Sommeren, et aI., 
1993). 
Matrix-O-C(O)-CH2-NH-(CH2),-COOH + H2N-mini-Mab 
--> Matrix-O-C(O)-CH,-NH-(CH2),-CO-NH-mini-Mab + H20 (3) 
Epoxy Activated matrix is 4 % cross-linked agarose and its epoxy group binds to amines 
of the ligands via 12-atom spacer of oxygen and carbon (Eq. 4). 
Matrix-O-CH2-CH(OH)-CH,-O-(CH2).-CH2-CH(O)-CH2 + H2N-mini-Mab 
--> Matrix-O-CH,-CH(OH)-CH,-O-(CH2)4-CH,-CH(OH)-CH,-NH-mini-Mab (4) 
Korah et aI. (2003a) has tested CNBr Sepharose™ and Actigel™ for PC 
purification using pure PC. Actigel™ showed a PC purification efficiency higher (10%) 
than CNBr Sepharose™ (6 %), indicating that the matrix with a longer spacer arms may 
keep the 3-D structure of the immobilized mini-Mab better. 
2 mg of the mini-Mab was reacted with 1 ml of each matrix. The mini-Mab 
immobilization efficiencies of the CNBr Sepharose™, Actigel™, NHS Sepharose™, and 
Epoxy Activated™ matrices were approximately 85, 85, 95, and 70 %, respectively, 
showing NHS Sepharose with the highest (Table 6). Each matrix was packed in a 
column, the PC performance was tested using 20 fig of pure PC, and the PC in the eluate 
was quantified by ELISA (Table 6). The purification efficiency was presented as a 
normalized PC amount per 1 mg of the immobilized mini-Mab on the matrices. CNBr 
Sepharose ™ showed the worst purification efficiency probably because the mini-Mab 
bound to the matrix via a very short spacer, losing its original three dimensional 
conformations (Kang, et aI., 1992). Actigel™ showed a reasonable performance and 
NHS Sepharose ™ has shown the best performance for the PC purification (54 %). 
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Sepharose™*l Sepharase ™ Activated™ 
Length of the spacer 
1 5 10 12 
(number of atoms) 
Mini-Mab 
immobilization 0.85 0.S5±0.03 0.95±0.02 0.7 
efficiency"(el) 
PC purification yield" (e2) 0.06±0.01 O.4S±O.IS 0.54±0.11 OJO±0.07 
Normalized PC purification 
1.l±OJ 5.6±2.1 5.7±1.8 4.9±1.0 
yield ().lg-PC/mg-mini-Mab) 
Matrix productivity 
0.05 0.41 0.51 0.21 
(el x e2) 
'I: The study uSing CNBr Sepharase was performed by Korah (2002). 
'2 (el) and '3 (e2): The related information was reported by Kang, et al. (1992). 
The normalized PC purification yield of NHS Sepharose ™ showed that I O-atom 
spacer arms have kept the activity of the immobilized mini-Mab well. Epoxy 
Activated™ has spacers longer than NHS Sepharose™ but showed lower immobilization 
efficiency than other matrices and also the immobilized mini-Mab on the gel showed a 
purification performance inferior to that of Actigel™ or NHS Sepharose TM. Kang, et al. 
(1992) evaluated the matrix performance by the coupling efficiency of ligand (El), the 
product adsorption efficiency of ligand (£2), and the specific activity of the eluted product 
(E3). Here, the mini-Mab immobilization efficiency (El) and PC purification yield (E2) of 
the matrices were used to study the PC purification performance, assuming that the 
activities of the purified PC by the matrices are the same. The NHS Sepharose™ showed 
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the best PC purification performance and, therefore, NHS Sepharose ™ was selected for 
the further PC purification studies. 
3. PC Purification from the PC Homologues Mixture 
As previously stated, PC sources, plasma and Cohn Fraction IV -I include many 
proteins homologues to PC and these homologous proteins are coagulants. To study the 
optimal amounts of the mini-Mab immobilized on NHS Sepharose ™ for PC purification, 
2, 4, and 6 mg of the purified mini-Mab were immobilized on I ml of the NHS 
Sepharose ™ matrix each. A mixture of PC and PC homologous coagulant factors was 
used as a source material and PC purification performance of each matrix was studied. 
Commercially available PC homologous blood clotting factors were mixed with 
PC following the physiological ratio in plasma, i.e., PC, 4; factor II, 90; factor VII, 0.5; 
factor IX, 4; and factor X, 6.4 J.lg/ml. The actual amounts of proteins were: PC, 20; 
factor II, 450; factor VII, 2.5; factor IX, 20; and factor X, 32 J.lg, in the final volume of 
500 J.ll. PC and PC-homologues in the fraction at various chromatography steps were 
quantified by ELISA (Table 7). 
When 2 mg of the mini-Mab was used, approximately 85 % of PC was washed 
away, showing much less adsorption compared with the case with PC only. 
Nevertheless, more than 95 % of PC homologues were also washed away. During the 
elution process, 14 % of PC yield was recovered, much less than when the pure PC was 
used as the source material (54%). For the PC homologues, less than 5 % of PC 
homologues remained in the eluate. However, the amount of factor II in the eluate was 
greater than that of PC, because of its large amount in the source material (more than 20 
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times greater than PC). Factor IX, which showed a high affinity to the mini-Mab for the 
ELISA did not remain in the column. 
For the matrix with 4 mg of the mini-Mab, 73 % of PC was washed away, 10 % 
less than that with 2 mg. As in the matrix with 2 mg ofmini-Mab, more than 95 % of PC 
homologues were washed away. The amount of factor II in the eluate was less than that 
of PC. During elution, yield of26 % was obtained. 
Table 7. PC purification efficiency when 2 mg, 4 mg, or 6 mg of the mini-Mab 
was immobilized in 1 ml of the matrix. The source material was the mixture of PC 
and four PC homologues. [Experiment conditions: 0.015 cm/s of linear velocity, 
and 10 minutes of reaction time 1 






PC FIl FVII FIX FX 
--
2 Ilg 
17.1±1 44l±1 2.5±0.1 19.6±0.1 30.2±0.6 
(%) (85±3) (98±0.3) (99±!) (98±0.!) (95±2) 
Washing 4 Ilg 
14.6±1 44l±5 2.4±0.1 !9.7±0.2 30.7±0.! 
(%) (73±9) (98±!) (97±2) (98±!) (96±0.!) 
6 Ilg 
14.6±1 442±5 2.4±0.! !9.6±0.3 31.2±0.9 
(%) (73±3) (98±!) (95±3) (98±1) (97±3) 
2 Ilg 
2.7±! 5±1 0 0.l±0.1 1.l±1.2 
(%) (l4±3) (1±0.2) (0) (0.3±0.2) (3±4) 
Elution 4 Ilg 
5.2±! 5±5 0.1±0.! 0.1±0.1 0.5±0.4 
(%) (26±4) (1±1) (2±3) (0.7±0.7) (2±1) 
I 6 
I 
Ilg 5.2±1 7±4 0.1±0.! 0.2±0.2 0.7±0.8 
I 
(%) (26±3) (2±1) (4±5) (1.l±1.0) (2±2) 
. -~--. .-_ . 
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For the NHS matrix with 6 mg of the mini-Mab, 73 % of PC was washed away, 
which is similar to that with 4 mg of mini-Mab, and more than 95 % of PC homologues 
were washed away. The PC purification yield of 26 %, similar to that of the matrix 
immobilized with 4 mg ofmini-Mab, was obtained. The amount of factor II in the eluate 
was greater than that of PC. The amounts of other PC homologues in the eluate (factors 
II, IX, and X) were slightly more than those in the case of the 4 mg mini-Mab. 
This study result shows that the NHS Sepharose matrix with 4 mg mini-Mab 
showed the best performance and was used for further studies for PC purification from 
Cohn Fraction IV-\' The result also shows that PC purification yield decreases 
significantly when there are other PC homologous proteins exist in the source material 
and the amount of factor II in the eluate is similar to or slightly more than that of PC. 
4. Purification of PC from Cohn Fraction IV-I 
Quantification of PC and PC Homologues. It has been reported that I kg of Cohn 
Fraction IV -I paste had approximately 100 mg of PC (Wu, et aI., 1998). The 
concentrations of the PC homologues in Cohn Fraction IV -I, however, have not been 
quantified. Here, PC and the PC homologues in the Cohn Fraction IV -I were quantified 
using ELISA. 
Following Wu's protocol (2000b), approximately 22 g of Cohn Fraction IV-I 
paste was dissolved in 440 ml of sodium citrate buffer (approximately 20 times dilution 
ratio; pH 6.0) and placed for 5 hours, at 4 DC, with stirring at 100 rpm. After the 
centrifugation of the paste solution at 4000 rpm for 20 minutes, PC and the homologues 
in the supernatant were quantified using ELISA (Table 8). 
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Table 8. Amounts of PC and PC homologues in Cohn Fraction IV-I paste. 
------ ,-- ----" ..• -------- . ----------- -,., •.. ___ 0'_. ----_.-
PC FII FVII FIX FX HSA 
. __ .. _-
Human plasma 4 90 0.5 4 6.4 40000 
(Ilgiml) [1]' [23] [0.13] [1] [1.6] [ 10000] 
Supernatant of Cohn 
103.9±3.4 1201±178 29.3±5.7 13.5±3.1 269±18 24812±5720 
Fraction IV-1 
[1] [12] [0.3] [0.13] [2.6] [239] 
(mglkg-paste) 
After the filtration of 
95.5±2.3 1171±15 20±1.2 9.2±0.2 264±9 22777±4410 
Cohn Fraction IV-1 [II [12] [0.2] [0. I] [2.8] [239] 
(mg/kg-paste) 
[ ]*: the numbers In brackets are showmg the ratio of the amount of factors to PC amount. 
The amount of PC in the supernatant was determined to be approximately 100 
mglkg-paste and the ratio of the amount of factors VII and IX to that of PC's was much 
less. The amounts of factor X was approximately 3 times more than that of PC. The 
amounts of factor II was shown to be approximately 1200 mg/kg-paste. For human 
serum albumin (HSA), which is the most abundant protein in plasma, the amount ratio to 
that of PC was forty times less than that in plasma. 
The supernatant was then filtered using polyethersulfone filters (0.8, 0.45, and 0.2 
flm of pore sizes, respectively) to remove particulate before applying it to mini-Mab 
immobilized gel matrix [or the PC purification. After filtration, approximately, 8 % less 
amount (96 mg/kg-paste) of PC and 2-32 % less homologues were found in the filtrate 
(factor II; 1171, factor VII; 20, factor IX; 9.2, and factor X; 264 mglkg-paste). 
Effect of Adsorption pH on PC Purification Performance. The usual pH used for 
either plasma or in Cohn Fraction IV -1 is 6.0, to reduce the activity of protease present in 
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plasma (Amaral, et aI., 2003; Vazquez-Lopez, et aI., 1999). ELISA was carried out to 
study the affinity of the mini-Mab to PC at pH 6 and 7. The mini-Mab at pH 7 showed 
the affinity to PC 30 - 40 % higher than that in pH 6 (data not shown). Next, the effect 
of pH on the performance of the mini-Mab immobilized, PC affinity chromatography was 
studied. The pH of the source material was also adjusted to either pH 6 or 7. 4 ml of the 
Cohn Fraction IV -1 filtrate (total PC amount, 15 /-lg) was applied to the mini-Mab 
immobilized NHS matrix and the PC purification was performed. The amount of PC at 
various purification stages were determined by ELISA (Table 9). 
Table 9. Amount of PC and PC homologues in various fractions during 
purification process from Cohn Fraction IV-l at pHs of 6.0 and 7.0. The amount 
of the factors in washing and elution. [Experiment conditions: 1 ml of gel matrix, 
0.015 cm/s oflinearvelocity, and 10 minutes of reaction time] 




PC FII FVII FIX FX 
6 /!g 
1l±2 464±209 1.2±0.5 1.3±0.4 2.7±O.l 
(%) (73±8) (93±7) (98±1) (86±9) (96±5) 
Washing 
/!g 1l±2 475±180 1.2±0.5 1.3±0.5 4±2.2 7 
(%) (73±17) (96±1) (99±1) (86±14) (94±2) 
6 /!g 
2.4±0.3 1.2±0.1 0 0.003±0.001 0.0l± 0.003 
(%) (l6±1) (O.3±O.l) (0) (O.3±O.l) (O.4±O.l ) 
Elution 
7 /!g 
1.7±O.l 0.9±0.1 0 0 0.003±0.003 
(%) (ll±l) (0.2±O.l ) (0) (0) (0.l±0.1) 
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In the washing step, 73 % of PC was washed away for both pHs with the similar 
percentage of washing for PC homologues. For factor 11,93 and 96 % were washed away 
for pH 6 and 7, respectively. Approximately 98 and 95 % of factors VII and X were 
washed away for both pHs, respectively. For factor IX, approximately 86 %, less than 
the other factors, was washed away. 
In the eluate, the amount of factor II was found to be half of the actual PC 
amount. For the other factors, less than 0.4 % was found in the eluate for both pHs. The 
PC in the eluate quantified by ELISA was shown to be 16 and 11 % at pHs of 6 and 7 
respectively, showing approximately 5 % higher yield with pH 6, and possible PC 
degradation at pH 7.0. The yield of 16 % at pH 6.0 from the Cohn Fraction IV-l is also 
almost a half of the yield from PC homologues mixture (26 %). 
Effect of HSA in the source material on PC Purification Performance. As 
previously shown, there is a reduction in the purification yield for the sample of the 
mixture of PC and PC homologues compared with the sample with PC only. In the 
presence of large quantity of other molecules, PC molecules do not get to be transported 
to the mini-Mab well. Although human serum albumin (HSA) in Cohn Fraction IV -1 is 
only 1/30 of that in plasma, the amount is still 240 times greater than that of PC. 
Therefore, it was speculated that this large amount of HSA may hinder the diffusion of 
PC molecules. Therefore, the effect of the presence of large amount of HSA in the 
source material on PC purification was systematically studied. Sample composed of PC 
and PC homologues at a physiological concentration ratio in plasma (PC, 20; factor II, 
450; factor VII, 2.5; factor IX, 20; and factor X, 32 Ilg) with or without HSA (0.2 g) was 
applied to the mini-Mab immunoaffinity chromatography column and the purification 
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process was performed. Each factor in washing and elution steps was quantified by 
ELISA (Table 10). 
In the washing step, for the sample without HSA, approximately 75 % of PC was 
washed away and for the samples with HSA, 88 %. For factor VII, 87 and 82 % were 
removed for the samples without and with HSA, respectively. For other factors, more 
than 96 % was removed. 
In the elution, the PC purification yields were shown to be 12 and 25 % for the 
samples with and without HSA, respectively, showing that, with HSA in the source, the 
yield is reduced by approximately 13 %. The results show that the large quantity of HSA 
in the source material interferes the PC purification yield. 
Table 10. Effect of HSA on PC purification. The amount of the factors in 
washing and elution steps (a) without and (b) with HSA. [Experiment conditions: 
1 ml of gel matrix, 0.015 cm/s of linear velocity, and 10 minutes of reaction time] 
Amount of factors 
Purification 
steps 
PC FII FVII FIX FX HSA 
(a) Ilg 
15±1.4 445±0.6 1.7±1.l 19.5±0.2 31±0.1 0 
(%) (75±7) (99±0.1) (87±I3) (97±2) (98±0.2) (0) 
Washing 
(b) Ilg 
18±0.4 448±0.5 2.1±O.l 19.5±0.4 31±0.4 198934±1323 
(%) (88±2) (99.6± 0.1) (82±4) (97±2) (96±4) (99.5±0.6) 
(a) Ilg 
4.9±1.3 2.1±0.6 0.2±0.3 0.2±0.1 0.3±0.1 0 
(%) (25±7) (0.5±0.1) (9±1) (1.3±0.4) (0.9±0.3) (0) 
Elution, 
(b) Ilg 
2±0.3 0.6±0.1 0.5±0.1 0.02±0.01 0.2±0.2 40.9±23 
(%) (12±2) (0.1±0.01) (l7±4) (0.2±0.1) (0.6±0.5) (0.02±0.0 I) 
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Effect of Salt on PC Purification. Since large amount of HSA in the source 
material affects PC purification yield significantly, it was also speculated that HSA 
molecules get adsorbed to the gel matrix non-specifically and prevent PC molecules from 
reacting with their mini-Mabs. The concentration of NaCI in washing buffer in the 
original protocol was 0.08 M and the washing buffer with 0.5 M of NaCI was tested. 
Cohn Fraction IV -1 with the PC amount ranging 15 - 20 Ilg was applied to the column 
and the PC purification was performed using the washing buffer at 0.5 M NaCl. The PC 
and PC homologues in washing and elution steps were quantified using ELISA (Table 
11 ). 
Table 11. Effect of the salt concentration in washing buffer on the purification of 
PC from Cohn Fraction IV-I. The amount of the factors in washing and elution 
steps when the washing buffer contains (a) with 0.08 and (b) 0.5 M NaCl. 
[Experiment conditions: 1 ml of gel matrix, 0.015 cm/s of linear velocity, and 10 
minutes of reaction time] 
Amount of factors 
Purification 
steps 
PC FII FVII FIX FX HSA 
(a) Ilg 
11±0.4 533±90 4±4 1.2±0.5 6.2±2.7 5737±19 
(%) (77±3) (98±0.5) ( 97±2) (98±0.1) (98± 1) (99±1) 
Washing 
(b) Ilg 
18±2.3 618±21 3±1 1.0±0.4 7.5±0.6 6725±35 
(%) (97±3) (97±4) (89±8) (99.5±0.7) (99±1) (99.8±0.1) 
(a) Ilg 
2±0.1 l.3±0.1 0 0 0.1±0.01 4±3.1 
(%) (l5±0.4) (0.2±0.1) (0) (0) (1.6±0.1) (0.1± 0.01) 
Elution 
(b) Ilg 
0.1±0.1 0.7±0.2 0.5±0.5 0 0.02±0.01 15±0.3 
(%) (0.3±0.1) (0.1±0.01) (1l±2) (0) (0.3±0.1) (0.1± 0.01) 
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During the washing step, for the washing buffer with 0.08 M NaCl, 77 % of PC 
was washed away, while 97 % of PC was removed for the buffer with 0.5 M NaCl. For 
other factors, more than 97 % were removed during the washing step both cases, but 
factor VII showed less amount of washing for using the buffer with 0.5 M of NaCl. In 
the elution, the PC purification yields were IS and OJ % when the washing buffer had 
0.08 M and 0.5 M of NaCl, respectively, showing that high salt concentration affects the 
PC adsorption to the mini-Mab. For other factors, less than 2 % remained for both cases 
except the factor VII remained more with 0.5 M NaCl. 
5. Electrophoresis of Eluate of the PC Chromatography using Cohn Fraction IV-l 
Electrophoresis was performed for commercially available PC, PC homologous 
factors, human serum albumin, and the fractions from the PC purification process from 
the Cohn Fraction IV -I under non-reduced condition (Figure IS). 
2 3 4 5 6 7 8 Lane 
1; PC 
2; factor 11 
3; facto r VII 
4; factor IX 
5; factor X 
6; HSA 
7; Cohn Fraction IV-l 
8; PC eluate. 
Figure IS. Electrophoresis ofthe samples from PC purification from Cohn 
Fraction IV -I using the mini-Mab immobilized NHS Sepharose ™ 
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The result showed that the mini-Mab PC affinity chromatography removed the 
proteins with molecular weights lower than PC. There are a single band around the 
molecular weight of PC (PC, factor II and human serum albumin, based on ELISA 
result). Two bands at the molecular weights greater than PC were also found in the 
eluate. 
6. Removal ofHSA by DEAE Ion Exchange Chromatography 
The isoelectric point (PI) of PC is 4.4~4.8 and the pI of HSA is 5.7 (Bordbar, et 
aI.,2004). From the fact that a low PC purification yield occurs with the source material 
with high HSA concentration and there is a difference in pI between PC and HSA, ion 
exchange chromatography was considered to remove HSA before the mini-Mab affinity 
chromatography step. 
Approximately 1 ml of the DEAE Sepharose™ Fast Flow matrix was packed in a 
col umn of the diameter at 0.7 cm. Then 100 ml of a filtered Cohn Fraction IV -1 solution 
was applied to the column and ion exchange chromatography was performed using a pH 
of 6.0 for adsorption/washing. PC, PC homologues, and HSA in washing and elution 
steps were quantified by ELISA (Table 12). 
The yield of PC was approximately 65 % and 1 0 ~ 20 % of factors II, FIX, and 
FX were removed. 95 % of factor VII was removed. For the HSA, more than 99 % was 
washed away. The concentration of PC and PC homologues in the eluate became 10 
times higher than that in the source, except the factor VII. 
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Table 12. The amount of PC, PC homologues, and HSA in the DEAE eluate of 
Cohn Fraction IV-I. [Experiment conditions: 1 ml of gel matrix, 0.004 cm/s of 
linear velocity, and 4°C] 
PC FII FVII FIX FX HSA 
Amounts in the 
644 10428 57 43 462 58857 source /lg 
Washing, /lg 214 787 53 5.5 31 58723 
(%) (33.3) (7.5) (94.4) (13) (6.7) (99.8) 
Elution /lg 
420 8712 3 36.2 420.4 40.1 
(%) (65.3) (83.6) (5.3) (85) (90.9) (0.07) 
Cone. in the source /lg/ml 6.4 10.42 0.57 0.42 4.6 590 
Cone. in the eluate /lg/ml 39 800 0.29 3 39 4 
In summary, DEAE anion exchange chromatography removed most of the HSA 
and, PC and factors II, IX, and X were concentrated. 
7. PC Purification from the Eluate ofDEAE Chromatography Using the NHS Matrix 
The affinity purification of PC from the eluate ofDEAE chromatography of Cohn 
Fraction IV -1 was performed using the mini-Mab immobilized NHS matrix. The amount 
of PC of the DEAE eluate was approximately 20 ~g and the amounts of HSA in the 
eluate was approximately 4 ~g. PC, PC homologues, and HSA in elution step were 
quantified using ELISA (Table 13). 
Approximately 25 % of PC purification yield was obtained, 9 % higher than that 
without the ion-exchange process (16 %). This result confirms that the large amount of 
HSA in the source material affects the adsorption of PC to the mini-Mab on the matrix. 
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Table 13. PC purification from the DEAE eluate of Cohn Fraction IV-l using 
mini-Mab immobilized NHS matrix. [Experiment conditions: 1 ml of gel matrix, 
0.015 cm/s oflinearvelocity, and 10 minutes of reaction time] 
PC FII FVII FIX FX HSA 
Amount in the 
20 173±7 0.2±0.1 l.5±0.1 24±4 4±1.4 
source !!g 
Amount in the !!g 4.9±O.l 2.5±1.4 0.l±0.1 0 0.l±0.02 0.3±0.01 
eluate (%) (25±0.3) (l.5±0.9) (18±25) (0) (0.2±0.1) (l0±4) 
The overall PC purification yield from Cohn Fraction IV -1 is combined value of 
the yield from DEAE anion exchange chromatography from Cohn Fraction IV-l (65 %) 
and the yield (25 %) by mini-Mab immobilized NHS matrix using the eluate. It is 
approximately 16 %, and is similar to the PC purification yield from Cohn Fraction IV-l 
without the ion-exchange process. For the other factors, the overall yields from Cohn 
Fraction IV -1 were similar to the values of the combined yields from both DEAE anion 
exchange chromatography from Cohn Fraction IV -1 and the purification from the eluate. 
8. Electrophoresis of Eluate of the PC Affinity Chromatography Using DEAE Eluate 
Electrophoresis was performed for the eluate of the mini-Mab immunoaffinity 
using the eluate of DEAE chromatography, under a non-reduced condition (Figure 16). 
The PC eluate showed that there is a band around 60,000 Da, possibly for PC, factor II, 
and HSA. Two bands are shown at molecular weights greater than PC. 
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2 3 4 5 6 7 8 9 Lane 
I; PC 
2; factor 11 
3; factor Vll 
4; factor IX 
5; factor X 
6; HSA 
7; Cohn Fraction rV-I 
8; DEAE eluate 
9. PC eluate 
Figure 16. Electrophoresis of the eluate of PC purification using the mini-
Mab immobilized NHS Sepharose™ with the source of the DEAE eluate. 
D. ECONOMIC ANALYSIS OF PC PURIFICATION BY MINI-MAB 
A preliminary economic analysis of PC purification using the mini-Mab was 
performed by Korah, et al. (2003). The specific production rate of mini-Mab was 
evaluated to be 500 times faster than that of Mab's . With pure mini-Mab, not the 
supernatant from the reactor broth, the yield of Mab purification (70 %) was evaluated 
1.75 times greater than mini-Mab's (40 %) based on mini-Mab purification using IMAC. 
For PC purification study, Korah used pure PC instead of Cohn Fraction IV-I. PC 
purification yield using Mab (70 %) was 7 times better than that using mini-Mab's (10 
%). 
For the overall economic analysis, Korah (2003) estimated that PC purification 
using the mini-Mab is 40 times cheaper than that using regular Mab. 
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Table 14. An economic analysis of the production for the mini-Mab using E. coli 
and for the Mab using animal cell culture. (modified from Korah's analysis, 2003) 
Mini-Mab Mab 
Total cost of Media ($IL) 6.09 Total cost of Media ($/L) 60.18 
2XTY 3.45 DMEM· 27.5 
IPTG 1.82 Calf serum 30.0 
Ampicillin 0.59 Antibiotic 2.68 
Glucose 0.23 
Production time (day) 1 Production time (day) 4 
Production level (g/L) 0.45 Production level (g/L) 0.1 
Molecular weight (kDa) 30 Molecular weight (kDa) 150 
Overall production rate 2.5 x10-6 
Overall production rate 2_8xlO-9 
(mole/day/dollar) (mole/day/dollar) 
Dulbecco's modification of Eagle's Media 
Since Korah's preliminary study, there has been more optimization in the mini-
Mab production and the new production rate of the mini-Mab was estimated to be 1000 
times better than that of Mab's (Table 14). The mini-Mab purification yield from the 
source of the reactor broth was improved and became 34 % by commercially available 
protein A affinity chromatography. The yield of PC purification from Cohn Fraction IV-
1 is 16 %. 
With these new improvements, PC purification using mini-Mab was re-estimated 
as approximately 100 times cheaper than that using regular Mab (Table 15). 
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Table 15. Economic analysis of PC purification using mini-Mab and regular Mab. 
Mini-Mab Mab 
Production cost 1 1000 
Antibody purification 2 1 
PC purification 4.5 1 




The following Conclusions were made for PC production process from Cohn 
Fraction IV-1 using mini-Mab produced by recombinant E. coli in this study. 
Mini-Mab production. Out of the thirteen HB2151 E. coli colonies, E4FX was 
confirmed to be the colony producing the mini-Mab the most and was selected for the 
optimization of the mini-Mab production. 
The optimum conditions for the mini-Mab production were determined to be 0.1 
% glucose; 0.1 mM IPTG; initial pH 5.5 ~ 6.0; the harvest time of the 18 hrs; and media 
temperature at 23 ~ 30 T. The mini-Mab production level was increased from 15 mg/L 
to 450 mg/L after the optimization of the culture conditions. PMSF in the production 
media negatively affects the mini-Mab production. The best way of storing the mini-Mab 
produced media is at -70°C. If the media has to be stored at 4 °c for some reason, the 
cells should be removed first and stored with PM SF . 
Mini-Mab Purification. Using commercially available protein A Sepharose, the 
mini-Mab was purified from the supernatant of the production media at a yield of34 %. 
PC purification. PC purification performance was tested for the mini-Mab using 
four commercially available gel matrices. For pure PC, NHS Sepharose™ showed the 
best PC purification efficiency of 54 %. 
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The optimum amount of the mini-Mab for PC purification was determined to be 4 
mg ofmini-Mab per 1 ml ofNHS Sepharose™ gel matrix. 
Cohn Fraction IV -1 is an inexpensive source for PC. The amounts of PC in the 
fraction were determined to be 104 mg-PClkg-paste. When Cohn Fraction IV -1 is used, 
PC purification yield using the mini-Mab immobilized NHS Sepharose™ was 16 %, 
much lower the case with pure PC. When samples of the PC and PC homologues 
mixture with and without HSA were tested, the yield of 25 % was obtained without HSA, 
while 13 % was obtained with HSA. DEAE anion exchange chromatography was able to 
remove 99.8 % HSA from Cohn Fraction IV-1 and 65 % of PC was retained in the eluate. 
Also PC was concentrated approximately 10 times during the process. PC purification by 
the mini-Mab immobilized NHS Sepharose™ showed 25 % of the PC purification yield 
from the eluate ofDEAE chromatography of Cohn Fraction IV-I. 
A brief economic analysis showed that the PC purification cost using the mini-




The following studies are suggested for future studies, to improve PC purification 
using mini-Mab. 
Mini-Mab production. It is suggested to produce mini-Mab in a single step 
instead of the two stages of growth and production. Scale-up of mini-Mab production 
may be beneficial, especially using bioreactors. 
Mini-Mab purification. Mini-Mab purification using IMAC may also be studied 
as an inexpensive process. 
PC purification. Recycling of the PC source material back to the column during 
the adsorption step may minimize the loss of PC in the source material. Mechanism of 
HSA interfering PC purification may be investigated. Developing mini-Mab 
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NOMENCLATURE 
aPC: Activated Protein C 
BCA: Bicinchoninic Acid 
BSA: Bovine Serum Albumin 
CNBr: Cyanogen bromide 
DEAE: Diethylaminoethyl 
DI water: Deionized Water 
DMEM: Dulbecco's Modification of Eagle's Medium 
E. coli: Escherichia coli 
ELISA: Enzyme Linked Immunosorbent Assay 
FII: human blood factor II 
FVII: human blood factor VII 
FIX: human blood factor IX 
FX: human blood factor X 
FDA: Food and Drug Administration 
Fv: Variable Fragment 
HIT: heparin induced thrombocytopenia 
HRP: Horseradish Peroxidase 
HSA: Human Serum Albumin 
ICUs: Intensive Care Units 
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IDA: Iminodiacetic Acid 
IgG: Immunoglobulin G 
IMAC: Immobilized Metal Affinity Chromatography 
IPTG: Isopropyl P-D-thiogalactopyranoside 
LPS: Lipopolysaccharides 
Mab: Monoclonal Antibody 
Mini-Mab: Mini-Antibody 
MW: Molecular Weight 
NHS: Normal Hydroxysuccinimide 
NT A: Nitrilotriacetic acid 
O.D.: Optical Density 
OPD: O-phenylenediamine Dichloride 
PC: Protein C 
PCC: Prothrombin complex concentrate 
PEG: Polyethylene Glycol 
pI: Isoelectric point 
PMSF: Phenylmethylsulfonyl Fluoride 
rhPC: Recombinant Human PC 
scFv: Single-chain Variable Fragment 
SDS-P AGE: Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis 
TBS: Tris Buffered Saline 
TBST: Tris Buffered Saline with Tween 20 
TEMED: Tetrameth yleth yl enediamine 
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V H: Variable Region in a Heavy Chain 
V L: Variable Region in a Light chain 
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